E-LIB Suche - Ergebnisse für: Bahlis, N.

1

B08 IDECABTAGENE VICLEUCEL VERSUS STANDARD REGIMENS IN PATI..:

Rodríguez-Otero, P ; Ailawadhi, S ; Arnulf, B...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171743/. , 2023

Link: http://www.ncbi.nlm.nih...

2

P32 MAJESTEC-1: CORRELATIVE ANALYSES OF TECLISTAMAB, A B-CE..:

van de Donk, N ; Cortes-Selva, D ; Casneuf, T...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171470/. , 2023

Link: http://www.ncbi.nlm.nih...

3

P09 DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE (D-RD) ..:

Weisel, K ; Kumar, S ; Moreau, P...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171703/. , 2023

Link: http://www.ncbi.nlm.nih...

4

P16 HEALTH-RELATED QUALITY OF LIFE FOR FRAIL TRANSPLANT-INE..:

Facon, T ; Plesner, T ; Usmani, S...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171558/. , 2023

Link: http://www.ncbi.nlm.nih...

5

P949: A PHASE 2 TRIAL OF ELRANATAMAB, A B-CELL MATURATION A..:

Lesokhin, A. M ; Arnulf, B ; Niesvizky, R...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430580/. , 2022

Link: http://www.ncbi.nlm.nih...

6

P922: HEALTH-RELATED QUALITY OF LIFE WITH TECLISTAMAB, A B-..:

Popat, R ; Moreau, P ; Usmani, S. Z...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431097/. , 2022

Link: http://www.ncbi.nlm.nih...

7

PB2014: TECLISTAMAB VS SELINEXOR-DEXAMETHASONE IN PATIENTS ..:

Rosinol, L ; Usmani, S. Z ; Bahlis, N...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429118/. , 2022

Link: http://www.ncbi.nlm.nih...

8

P940: SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN ..:

Suvannasankha, A ; Bahlis, N ; Trudel, S...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430614/. , 2022

Link: http://www.ncbi.nlm.nih...

9

PB2020: MAJESTEC-3: RANDOMIZED, PHASE 3 STUDY OF TECLISTAMA..:

Mateos, M. V ; Bahlis, N ; Costa, L...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431613/. , 2022

Link: http://www.ncbi.nlm.nih...

10

P897: UPDATED RESULTS FROM THE ONGOING PHASE 1 STUDY OF ELR..:

Dalovisio, A ; Bahlis, N ; Raje, N...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430032/. , 2022

Link: http://www.ncbi.nlm.nih...

11

P936: TIME TO RESPONSE, DURATION OF RESPONSE, AND PATIENT-R..:

Facon, T ; Kumar, S. K ; Plesner, T...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431303/. , 2022

Link: http://www.ncbi.nlm.nih...

12

P898: COMPARISON OF TECLISTAMAB WITH BELANTAMAB MAFODOTIN I..:

Delforge, M ; Usmani, S. Z ; van de Donk, N. W...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430970/. , 2022

Link: http://www.ncbi.nlm.nih...

13

B06: SUBCUTANEOUS TALQUETAMAB IN COMBINATION WITH DARATUMUM..:

Mateos, M ; Hari, P ; Bahlis, N...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9012119/. , 2022

Link: http://www.ncbi.nlm.nih...

14

Final analysis of the phase III non-inferiority COLUMBA stu..:

Usmani S. Z ; Nahi H ; Legiec W...
info:eu-repo/semantics/altIdentifier/pmid/35354247. , 2022

Link: https://hdl.handle.net/1..

15

P06: UPDATED RESULTS FROM THE PHASE 1/2 MAJESTEC-1 STUDY OF..:

Popat, R ; Usmani, S ; Garfall, A...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9009794/. , 2022

Link: http://www.ncbi.nlm.nih...